The short version of Melanotan II fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-30 and is reviewed periodically as new material appears.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
=== Spring/summer 2007: Old deaths examined, new deaths occur === Between the time of Cortez Jr.'s death and the announcement of his toxicology tests in late April, The Dallas Morning News published the results of a lengthy analysis of autopsy results between 2005 and 2007, conducted in concert with the Dallas County medical examiner's office, which suggested that as many as 17 deaths among adolescents during that period were attributable to cheese heroin, not including the Cortez death. The conclusion was based in part on the presence of both heroin and diphenhydramine in the blood of the deceased; additionally, the families of 11 victims confirmed the deceased had used cheese heroin. Some toxicologists questioned the results due to the absence of acetaminophen. Other experts argued that acetaminophen has a shorter half-life and might have been metabolized by the body prior to death. Susan Dalterio, a University of Texas at San Antonio pharmacology expert, insisted that the combination was unlikely to be a coincidence, as a person sleepy from diphenhydramine would be unlikely to be abusing heroin at the same time. It is common for users of heroin and other opioid drugs to take diphenhydramine-containing medications as an attempt to alleviate side effects resulting from histamine release induced by opioid administration, such as pruritus, as well as potentiate the sedative effects of the drug.
In May 2016, the company opened a $150 million temperature-controlled warehouse in North Charleston, South Carolina, near the Port of Charleston, then acquired Consolidated Distribution Corporation of Lombard, Illinois that August, making Lineage the largest customized redistribution network in the United States. Two months later, it was reported that Lineage was considering locating a large facility at New Century AirCenter in Gardner, Kansas, but the proposed location resulted in lawsuits from local residents, and Lineage scrapped the project in November 2017 "due to a change in customer needs", though the project had received unanimous approval from county commissioners in July. Lineage entered European markets in 2017, acquiring Partner Logistics, a large cold-chain storage supplier. The company purchased facilities from American Cold Storage, in the Midwest, and eight Los Angeles, California area warehouses from U.S. Growers Cold Storage, raising its employee roster to 7,200, with Lineage operating 120 temperature-controlled storage facilities. The company then expanded into the temperature-controlled logistics markets in Australia, New Zealand, and Sri Lanka, in November 2019, with the acquisition of Emergent Cold, then into Canada, in July 2020, acquiring Ontario Refrigerated Services Inc. During 2018, the company acquired 24 companies, including The Yearsley Group, the UK's largest Cold Storage and Haulage supplier, maintaining its second-largest status. The company also sold minority stakes worth $700 million.
=== Approaches of streaming media platforms === The rise in popularity of streaming content on platforms such as Netflix, Hulu, Max, and Amazon Prime Video brought easier media access for viewers, as well as decreased regulation of content for television. Since it has become easier for the public to access different media forms, including movies, TV series, or other programs worldwide, the popular streaming service Netflix demonstrates different approaches to mental illness with various portrayals. Amongst the series Netflix provided, the recent study exploring the series 13 Reasons Why found that the representations of mental-health phenomena positively influence the individual's perceptions in understanding perceived norms regarding mental health problems, such as reaching out to others for support and discussing suicide with people for prevention. 13 Reasons Why is a Netflix original with the plot surrounding a high school female, Hannah Baker, who commits suicide in the season one finale. Controversy around this TV show has arisen, especially surrounding the idea of linking Baker's suicide to a form of anger and revenge. Some argue that there is too much emphasis on how Hannah committed suicide, including the graphic visuals, and not enough focus on the true reasons behind ending her life. Others also emphasize how shows such as 13 Reasons Why simply skim over and cover only the surface of these issues and thus somehow desensitize something as important as suicide.
Sources: en.wikipedia.org
An anxiolytic (; also antipanic or anti-anxiety agent) is a medication or other intervention that reduces anxiety. This effect is in contrast to anxiogenic agents which increase anxiety. Anxiolytic medications are used for the treatment of anxiety disorders and their related psychological and physical symptoms.
Daptomycin is a cyclic lipopeptide antibiotic produced by Streptomyces filamentosus. Daptomycin consists of 13 amino acids, 10 of which are arranged in a cyclic fashion, and three on an exocyclic tail. Two nonproteinogenic amino acids exist in the drug, the unusual amino acid L-kynurenine (Kyn), only known to daptomycin, and L-3-methylglutamic acid (mGlu). The N-terminus of the exocyclic tryptophan residue is coupled to decanoic acid, a medium-chain (C10) fatty acid. Biosynthesis is initiated by the coupling of decanoic acid to the N-terminal tryptophan, followed by the coupling of the remaining amino acids by nonribosomal peptide synthetase (NRPS) mechanisms. Finally, a cyclization event occurs, which is catalyzed by a thioesterase enzyme, and subsequent release of the lipopeptide is granted. The NRPS responsible for the synthesis of daptomycin is encoded by three overlapping genes, dptA, dptBC and dptD. The dptE and dptF genes, immediately upstream of dptA, are likely to be involved in the initiation of daptomycin biosynthesis by coupling decanoic acid to the N-terminal Trp. These novel genes (dptE, dptF) correspond to products that most likely work in conjunction with a unique condensation domain to acylate the first amino acid (tryptophan). These and other novel genes (dptI, dptJ) are believed to be involved in supplying the nonproteinogenic amino acids L-3-methylglutamic acid and Kyn; they are located next to the NRPS genes. The decanoic acid portion of daptomycin is synthesized by fatty acid synthase machinery (Figure 2).
Root development in Arabidopsis thaliana is stimulated and modulated by serotonin – in various ways at various concentrations. Serotonin serves as a plant defense chemical against fungi. When infected with Fusarium crown rot (Fusarium pseudograminearum), wheat (Triticum aestivum) greatly increases its production of tryptophan to synthesize new serotonin. The function of this is poorly understood but wheat also produces serotonin when infected by Stagonospora nodorum – in that case to retard spore production. The model cereal Brachypodium distachyon – used as a research substitute for wheat and other production cereals – also produces serotonin, coumaroyl-serotonin, and feruloyl-serotonin in response to F. graminearum. This produces a slight antimicrobial effect. B. distachyon produces more serotonin (and conjugates) in response to deoxynivalenol (DON)-producing F. graminearum than non-DON-producing. Solanum lycopersicum produces many AA conjugates – including several of serotonin – in its leaves, stems, and roots in response to Ralstonia solanacearum infection. Serotonin occurs in several hallucinogenic mushrooms of the genus Panaeolus.
Sources: en.wikipedia.org
The Vasa is a Swedish 1628 ship found archaeologically and was very well preserved. Completely submerged for 333 years allowed for the wood to be completely waterlogged but pollution in the 20th century off of the city Stockholm was able to kill any microorganisms that would have feast on the wreck, like the shipworm. Vasa was sprayed with a PEG solution for 17 years followed by a period of drying which is ongoing.
INS: The insulin gene (INS) on chromosome 11p15 is one of the earliest identified non-HLA genes linked to T1D. A variable number tandem repeat (VNTR) polymorphism in the promoter region of the insulin gene affects its thymic expression, with certain alleles reducing the ability to develop immune tolerance to insulin, a key autoantigen in T1D. PTPN22: This gene encodes a protein tyrosine phosphatase involved in T-cell receptor signaling. A common single-nucleotide polymorphism (SNP), R620W, in the PTPN22 gene is associated with an increased risk of T1D and other autoimmune diseases, suggesting its role in modulating immune responses. IL2RA: The interleukin-2 receptor alpha (IL2RA) gene, located on chromosome 10p15, plays a crucial role in regulating immune tolerance and T-cell activation. Variants in IL2RA affect the susceptibility to T1D by altering the function of regulatory T-cells, which help maintain immune homeostasis. CTLA4: The cytotoxic T-lymphocyte-associated protein 4 (CTLA4) gene is another immune-related gene associated with T1D. CTLA4 acts as a negative regulator of T-cell activation, and certain variants are linked to impaired immune regulation and a higher risk of autoimmunity. T1D is considered a polygenic disease, meaning that multiple genes contribute to its development. While individual genes confer varying degrees of risk, it is the combination of several genetic factors, along with environmental triggers, that ultimately leads to disease onset.
=== Pain === A 2026 meta-analysis concluded that people taking melatonin supplements may experience relief from musculoskeletal pain similar in magnitude to the effects of typical analgesics. Although melatonin may be considered as an adjunct option for pain relief, it had only modest effects, and the quality of evidence for efficacy was low to moderate.
The United States military began executing airstrikes on vessels in the Caribbean Sea in September 2025, described by the administration of President Donald Trump as part of an effort to fight the flow of illicit drugs from Latin America to the US. In October, the strikes expanded to include vessels in the Eastern Pacific Ocean. The Trump administration has alleged, without producing public evidence, that the vessels were operated by groups it designated as narcoterrorists, including the Venezuelan organization Tren de Aragua and the Colombian far-left guerilla group National Liberation Army. As part of what was later unveiled as Operation Southern Spear, the US began deploying Navy warships and personnel to the Caribbean in mid-August. Trump announced on 2 September that the US Navy had carried out the first airstrike in the Caribbean on a boat from Venezuela, killing all 11 people aboard; he released a video of the incident, which Venezuelan sources said had occurred on 1 September. US officials said that this was a military operation against drug cartels in Latin America and that these military operations would continue. As of 19 September 2026, at least 234 people had been killed (including 17 who are missing and presumed dead) in at least 78 strikes on over 79 vessels and the US had made its first strike on a land target within Venezuela. On 12 June, Niño Guerrero, leader of Tren de Aragua, was killed in joint operation with the post-Maduro Venezuelan government.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.